166 results on '"Capri, Stefano"'
Search Results
2. Reprocessing single-use cardiac catheters for interventional cardiology. A cost-minimization model for estimating potential saving at departmental scale and national level
3. Screening for sickle cell disease: focus on newborn investigations.
4. Efficiency ratio and rocketing drug prices: old concerns and new possibilities
5. An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators
6. Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments
7. The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy’s multi-stakeholder pre-convention questionnaire
8. Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective
9. The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy's multi-stakeholder preconvention questionnaire.
10. The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach
11. Atherogenic Dyslipidemias: Unmet Needs and the Therapeutic Potential of Emerging and Novel Approaches and Drugs
12. Extracorporeal Photopheresis for Second-Line Treatment of Chronic Graft-versus-Host Diseases: Results from a Health Technology Assessment in Italy
13. Ethical Hurdles in the Prioritization of Oncology Care
14. An integrated valuation model for payer and investor
15. Is vaccination good value for money? A review of cost-utility analyses of vaccination strategies in eight European countries
16. Economic impact of adult obesity on health systems: a systematic review
17. Impact of one-year treatment with biotechnological drugs on work ability in patients with rheumatoid arthritis in Italy: a prospective real-life study
18. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination
19. Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis
20. An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy
21. Pricing Policies in the Pharmaceutical Sector
22. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer
23. Economic value of influenza vaccination
24. Guidance for future HTA applications to vaccines: The HPV lesson
25. Pricing of orphan drugs in oncology and rare diseases
26. A cost-effectiveness and budget impact analysis of apremilast in patients with psoriatic arthritis in Italy
27. Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy
28. Adjuvanted influenza vaccine for the Italian elderly in the 2018/19 season: an updated health technology assessment
29. Using HTA to lead decision on the use of adjuvanted trivalent inactivated influenza vaccine in Italy [Oral Presentation]
30. Cost Evaluation of Chronic Schizophrenic Patients During the First 3 Years After the First Contact
31. The Cost of Schizophrenia: Editorsʼ Introduction
32. A cost-effectiveness and budget impact analysis of apremilast in patients with psoriatic arthritis in Italy.
33. Adjuvanted influenza vaccine for the Italian elderly in the 2018/19 season: an updated health technology assessment.
34. I costi dei pazienti con patologie infiammatorie dell’intestino (Malattia di Crohn e colite ulcerosa). Studio real world in Italia
35. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population
36. DEFINING INNOVATION WITH RESPECT TO NEW MEDICINES: A SYSTEMATIC REVIEW FROM A PAYER PERSPECTIVE
37. Approaches to manage ‘affordability’ of high budget impact medicines in key EU countries
38. Cost of breast cancer based on real-world data: a cancer registry study in Italy
39. Ethical Hurdles in the Prioritization of Oncology Care
40. Valutazione economica di Bexsero
41. The economic value of influenza vaccination
42. L’osteoporosi in Italia: risorse utilizzate dal SSN e relativi costi
43. Health Technology Assessment di octocog alfa nel trattamento in profilassi dell'Emofilia A
44. I costi per le fratture osteoporotiche in Italia: cosa manca?
45. Il valore di octocog alfa nella gestione dell'Emofilia A
46. The importance of Health Technology Assessment for the recognition of the value of new products: the case of Rheumatoid Arthritis
47. Value of octofog alfa (Advate) in the management of Haemophilia A patients
48. L'osteoporosi in Italia: un'analisi delle risorse utilizzate
49. Valutazione HTA di un farmaco innovativo per il trattamento dell' osteoporosi post-menopausale: il denosumab
50. Risorse utilizzate dal servizio sanitario nazionale e relativi costi per la gestione dell’emofilia A
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.